Biologic Input Output Systems

Biologic Input Output Systems operates in the neurotechnology and medical-device segment at the intersection of peripheral nerve interfaces, prosthetics, robotics, and AI-enabled signal processing. Its stated differentiation is architectural: the Universal Neural Interface is intended to create a bidirectional connection between implanted peripheral-nerve electrodes and robotic limbs or digital devices. That design targets both motor control and sensory feedback, potentially addressing a broader user experience than systems focused only on controlling a prosthesis. The company also describes machine-learning methods for decoding neural signals and adapting control over time, which could support personalization across users and changing physiological conditions. The company appears to be an early-stage specialist rather than a scaled device manufacturer: it is private, founded in 2021, and recorded in the 11–50 employee range, with no disclosed funding or valuation. Its competitive progress will depend on clinical validation, durability and safety of implantation, regulatory execution, and integration with commercially viable prosthetic platforms.

The company’s trajectory reflects a transition from technology formation toward clinical and ecosystem development. Founded in 2021, Biologic Input Output Systems has built its product concept around the Universal Neural Interface, an implanted peripheral-nerve electrode system intended to provide two-way communication between users and robotic limbs or digital devices. The 2024 publication concerning a neural electrode indicates continued work on core interface hardware and related methods. In January 2025, a collaboration addressed improvement of an implantable neural interface, suggesting an effort to strengthen system performance through external technical relationships. The April 2025 appointment of Chris Duncan, MD as Chief Medical Officer is a meaningful organizational inflection point because it adds dedicated clinical leadership to a company developing an implantable medical device. The BIOS Registry further indicates attention to patient, caregiver, healthcare-professional, and clinical-trial engagement. The recorded employee band of 11–50 suggests a compact development organization. Future growth is therefore likely to be shaped by clinical evidence, regulatory progress, manufacturing readiness, and the ability to translate neural decoding into reliable prosthetic control.